Effects of Sibutramine on the Treatment of Obesity in Patients with Arterial Hypertension

Published on Feb 1, 2002in Arquivos Brasileiros De Cardiologia 1.32
· DOI :10.1590/S0066-782X2002000200006
Alessandra Nunes Faria10
Estimated H-index: 10
(Federal University of São Paulo),
Fernando Flexa Ribeiro Filho8
Estimated H-index: 8
(Federal University of São Paulo)
+ 3 AuthorsMaria Teresa Zanella20
Estimated H-index: 20
(Federal University of São Paulo)
Abstract
OBJECTIVE: To assess the effects of weight reduction with 10mg of sibutramine or placebo on blood pressure during 24 hours (ambulatory blood pressure monitoring), on left ventricular mass, and on antihypertensive therapy in 86 obese and hypertensive patients for 6 months. METHODS: The patients underwent echocardiography, ambulatory blood pressure monitoring, and measurement of the levels of hepatic enzymes prior to and after treatment with sibutramine or placebo. RESULTS: The group using sibutramine had a greater weight loss than that using placebo (6.7% versus 2.5%; p<0.001), an increase in heart rate (78.3±7.3 to 82±7.9 bpm; p=0.02), and a reduction in the left ventricular mass/height index (105±29.3 versus 96.6±28.58 g/m; p=0.002). Both groups showed similar increases in the levels of alkaline phosphatase and comparable adjustments in antihypertensive therapy; blood pressure, however, did not change. CONCLUSION: The use of sibutramine caused weight loss and a reduction in left ventricular mass in obese and hypertensive patients with no interference with blood pressure or with antihypertensive therapy.
  • References (8)
  • Citations (15)
Cite
References8
Published on Jan 1, 2000in Diabetes & Metabolism 3.74
Françoise Luyckx10
Estimated H-index: 10
,
Pierre Lefebvre43
Estimated H-index: 43
,
André Scheen70
Estimated H-index: 70
(University of Liège)
La steatohepatite non alcoolique (NASH) est une maladie dont l'identite et l'importance ont ete mises en exergue recemment. Elle est actuellement consideree comme une des hepatopathies les plus frequentes dans les pays occidentaux. Elle est souvent associee a l'obesite severe, particulierement a l'adiposite abdominale, et est intimement liee a divers marqueurs cliniques et biologiques du syndrome d'insulinoresistance. Ainsi, tant la prevalence que la severite de la steatose sont correlees au sex...
212 Citations
Published on Feb 1, 1991in Journal of the American College of Cardiology 16.83
Michael L. Lauer1
Estimated H-index: 1
,
Keaven M. Andsrson1
Estimated H-index: 1
+ 1 AuthorsDouglas E. Levy191
Estimated H-index: 191
236 Citations Source Cite
Published on Oct 1, 1999in International Journal of Obesity 5.16
D. L. Hansen2
Estimated H-index: 2
,
Søren Toubro46
Estimated H-index: 46
+ 2 AuthorsA.V. Astrup91
Estimated H-index: 91
(University of Copenhagen)
OBJECTIVE: To assess the contribution of a thermogenic effect to weight loss induced by eight weeks treatment with sibutramine (15mg/d) vs placebo in obese subjects. DESIGN: Randomised, placebo controlled, double blind study. SUBJECTS: Thirty-two (7 male, 25 female) healthy obese body mass index (BMI) 33.9 ± 0.5 kg/m 2 subjects completed the trial. MEASUREMENTS: Energy expenditure (EE) was measured by indirect calorimetry during a 32 h stay in a respiration chamber before and after 8 weeks treat...
133 Citations Source Cite
Fernando Flexa Ribeiro Filho8
Estimated H-index: 8
(Federal University of São Paulo),
Eduardo Cantoni Rosa7
Estimated H-index: 7
(Federal University of São Paulo)
+ 4 AuthorsM. T. Zanella10
Estimated H-index: 10
(Federal University of São Paulo)
In order to evaluate the influences of obesity and hypertension on left ventricular mass (LVM), we studied 121 women stratified into 4 groups: normotensive non-obeses (n = 25), hypertensive non-obeses (n = 30), normotensive obeses (n = 24) and hypertensive obeses (n = 42) according to their anthropometric and echocardiographic parameters and ambulatory blood pressure monitoring (ABPM). Hypertensive obeses showed higher LVM than the other groups - normotensive non-obeses, hypertensive non-obeses ...
10 Citations Source Cite
Published on Mar 1, 1998in Obesity Research
Helen M. Seagle13
Estimated H-index: 13
(Anschutz Medical Campus),
Dan H. Bessesen2
Estimated H-index: 2
(Anschutz Medical Campus),
James O. Hill84
Estimated H-index: 84
(Anschutz Medical Campus)
Abstract Sibutramine, a monoamine re-uptake inhibitor, has recently been approved by the Food and Drug Administration as a weight loss agent. Sibutramine lowers bodyweight in rodents by reducing energy intake and increasing energy expenditure. Sibutramine facilitates weight loss in human subjects, but it is not clear whether it acts on energy intake, energy expenditure, or both. The present study was a randomized clinical trial designed to assess the effects of sibutramine (at 10 or 30 mg/day) o...
85 Citations Source Cite
Published on Apr 1, 1987in American Journal of Cardiology 3.17
Douglas E. Levy191
Estimated H-index: 191
(Boston University),
Daniel D. Savage34
Estimated H-index: 34
(Boston University)
+ 3 AuthorsWilliam P. Castelli86
Estimated H-index: 86
(Boston University)
Of 6,148 original cohort and offspring subjects of the Framingham Heart Study who underwent routine evaluation, a healthy group of 347 men (aged 42 ± 12 years) and 517 women (aged 43 ± 12 years) was identified to develop echocardiographic criteria for left ventricular (LV) hypertrophy. Healthy subjects were defined as normotensive, receiving no cardiac or antihypertensive medications, nonobese and free of cardiopulmonary disease. Echocardiographic criteria (in accordance with the American Societ...
719 Citations Source Cite
Published on Mar 1, 1998in International Journal of Obesity 5.16
Françoise Luyckx10
Estimated H-index: 10
,
Claude Desaive8
Estimated H-index: 8
+ 4 AuthorsPierre Lefebvre43
Estimated H-index: 43
Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty
416 Citations Source Cite
C. Gundlah1
Estimated H-index: 1
,
K. F. Martin1
Estimated H-index: 1
+ 1 AuthorsSidney B. Auerbach26
Estimated H-index: 26
Because monoamine reuptake inhibitors and releasing agents both increase extracellular neurotransmitter levels, establishing in vivo experimental criteria for their classification has been difficult. Using microdialysis in the hypothalamus of unanesthetized rats, we provide evidence that serotonin- (5-HT) selective and nonselective reuptake inhibitors can be distinguished from the 5-HT-releasing agent fenfluramine by four criteria: 1) Systemic fenfluramine produces a much greater increase in 5-H...
110 Citations
  • References (8)
  • Citations (15)
Cite
Cited By15
Published on Aug 1, 2008in Expert Opinion on Pharmacotherapy 3.48
Bikash Sharma7
Estimated H-index: 7
,
David Henderson47
Estimated H-index: 47
Background: Obesity has become a global epidemic with recent estimates of > 400 million obese adults. Despite this, there are few safe and effective pharmacological interventions for obesity. Sibutramine is a weight loss agent, for use as an adjuvant to a comprehensive program of calorie restriction, exercise and behavioral therapy. Objective: The goal of this article is to review the available literature of pharmacological interventions for obesity and specifically to examine data with sibutram...
22 Citations Source Cite
Published on Nov 1, 2008in Sao Paulo Medical Journal 1.06
Hernani Pinto de Lemos Júnior4
Estimated H-index: 4
(Federal University of São Paulo),
Álvaro Nagib Atallah34
Estimated H-index: 34
(Federal University of São Paulo),
André Luis Alves de Lemos1
Estimated H-index: 1
(Federal University of São Paulo)
CONTEXTO: Hipertensao arterial sistemica e parte da sindrome metabolica relacionada a obesidade. OBJETIVO: Avaliar o efeito da sibutramina na pressao arterial sistemica de pacientes com sobrepeso e obesos atraves de uma revisao sistematica. METODOS: Tipos de estudos: todos os estudos devem ser controlados e aleatorios. A qualidade metodologica dos estudos selecionados foi acessada usando os criterios descritos no Cochrane Handbook; participantes: pacientes com sobrepeso e obesos; intervencao: si...
7 Citations Source Cite
Maria Alice de Gouveia Pereira1
Estimated H-index: 1
(Federal University of São Paulo),
Roberto Galvão4
Estimated H-index: 4
(Federal University of São Paulo),
Maria Teresa Zanella20
Estimated H-index: 20
(Federal University of São Paulo)
OBJECTIVE: The objectives of the present study were to evaluate the effects of oral potassium supplementation, associated with a hypocaloric diet and aerobic exercises, on plasma potassium levels, blood pressure and insulin resistance, in centrally obese, not well controlled hypertensive patients on diuretic therapy; waist to hip ratio >0.85 in women, and >0.95 in men; systolic blood pressure >140mmHg and 90mmHg and <105mmHg. METHODS: This was a prospective double-blind randomized study includin...
6 Citations Source Cite
Published on Jun 1, 2013in American Journal of Cardiovascular Drugs 2.74
Srividya Kidambi12
Estimated H-index: 12
(Medical College of Wisconsin),
Theodore A. Kotchen48
Estimated H-index: 48
(Medical College of Wisconsin)
Obesity is a global pandemic and with its rise, its associated co-morbidities are increasing in prevalence, particularly uncontrolled hypertension. Lifestyle changes should be an anchor for the management of obesity-related hypertension; however, they are difficult to sustain. Drug therapy is often necessary to achieve blood pressure control. Diuretics, inhibitors of the renin–angiotensin system, and dihydropyridine calcium channel blockers are often used as first trio, with subsequent additions...
8 Citations Source Cite
Eduardo Cantoni Rosa7
Estimated H-index: 7
,
Maria Tereza Zanella9
Estimated H-index: 9
+ 4 AuthorsOsvaldo Kohlmann12
Estimated H-index: 12
OBJECTIVE: Blood pressure(BP) and target organ responses to antihypertensive drugs are not well established in hypertensive obese patients. This study is aimed at evaluating the effects of obesity and adiposity distribution patterns on these responses. METHODS: 49 hypertensive obese women were designated to different groups according to waist to hip ratio measurements - 37 with troncular and 12 with peripheral obesity. Patients were treated for 24-weeks on a stepwise regimen with cilazapril alon...
4 Citations Source Cite
Published on Sep 1, 2003in Obesity Research
Su Hyun Kim3
Estimated H-index: 3
(Yonsei University),
Young-Mee Lee10
Estimated H-index: 10
(Korea University)
+ 1 AuthorsChung Mo Nam32
Estimated H-index: 32
(Yonsei University)
Objective: Sibutramine causes weight loss by suppressing the appetite and by promoting energy expenditure, but it can also increase blood pressure through a norepinephrine effect. The aim of this study was to provide a comprehensive meta-analysis of randomized, controlled trials on the effects of sibutramine on blood pressure and weight loss. Research Methods and Procedures: Twenty-one placebo-controlled, double-blind, randomized trials of sibutramine were identified using MEDLINE, EMBASE, and a...
88 Citations Source Cite
Published on May 10, 2004in JAMA Internal Medicine 19.99
David Arterburn28
Estimated H-index: 28
,
Paul K. Crane57
Estimated H-index: 57
(University of Washington),
David L. Veenstra41
Estimated H-index: 41
(University of Washington)
Background The primary goal of weight loss is to prevent or reduce obesity-associated morbidity and mortality by improving cardiovascular and metabolic risk factors. We conducted a systematic review to assess the efficacy and safety of sibutramine hydrochloride for weight loss. Methods In April 2002, we searched MEDLINE, EMBASE, the Cochrane Library, and 7 other computerized bibliographic search tools using the keywords "sibutramine," "Meridia," and "Reductil" (in all languages and all available...
212 Citations Source Cite
Published on Jul 8, 2009in Cochrane Database of Systematic Reviews 6.75
Andrea Siebenhofer24
Estimated H-index: 24
(Goethe University Frankfurt),
Klaus Jeitler14
Estimated H-index: 14
(Medical University of Graz)
+ 6 AuthorsKarl Horvath15
Estimated H-index: 15
(Medical University of Graz)
Background All major guidelines for antihypertensive therapy recommend weight loss. Thus dietary interventions that aim to reduce body weight might be a useful intervention to reduce blood pressure and adverse cardiovascular events associated with hypertension. Objectives Primary objectives To assess the long-term effects of weight-reducing diets in hypertensive patients on - all cause mortality - cardiovascular morbidity - adverse events (including total serious adverse events, withdrawal due t...
98 Citations Source Cite
Published on Mar 24, 2008in JAMA Internal Medicine 19.99
Karl Horvath15
Estimated H-index: 15
,
Klaus Jeitler14
Estimated H-index: 14
+ 4 AuthorsAndrea Siebenhofer24
Estimated H-index: 24
Weight loss is recommended in all major guidelines for antihypertensive therapy. We searched for randomized controlled trials investigating the effects of weightreducing diets, pharmacologic substances, and invasive interventions for weight reduction on patient-relevant end points and blood pressure (BP) in patients with essential hypertension. No information on the effects on patient-relevant end points was available. Patients assigned to weight loss diets, orlistat, or sibutramine reduced thei...
94 Citations Source Cite
Published on Mar 2, 2016in Cochrane Database of Systematic Reviews 6.75
Andrea Siebenhofer24
Estimated H-index: 24
(Medical University of Graz),
Klaus Jeitler14
Estimated H-index: 14
(Medical University of Graz)
+ 4 AuthorsThomas Semlitsch10
Estimated H-index: 10
(Medical University of Graz)
Background All major guidelines for antihypertensive therapy recommend weight loss. Thus dietary interventions that aim to reduce body weight might be a useful intervention to reduce blood pressure and adverse cardiovascular events associated with hypertension. Objectives Primary objectives To assess the long-term effects of weight-reducing diets in people with hypertension on all-cause mortality, cardiovascular morbidity, and adverse events (including total serious adverse events, withdrawal du...
25 Citations Source Cite